1 / 13

Presentation Spring 2004 medivir.se

Presentation Spring 2004 www.medivir.se. Medivir in brief. One of the world leaders in polymerase research. Aiming for a similar position in protease research. Unique competitive advantages in all clinical projects. Nine partnerships with eight companies and a broad

doris
Download Presentation

Presentation Spring 2004 medivir.se

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presentation Spring 2004 www.medivir.se

  2. Medivir in brief • One of the world leaders in polymerase research. • Aiming for a similar position in protease research. • Unique competitive advantagesin all clinical projects. • Nine partnerships with eight companies and a broad • network with academia in Europe and US. • Nordic marketing rights for all projects. • Located in Stockholm (Sweden) and Cambridge (UK) with • approximately 100 employees in R&D.

  3. Focused know-how base gives a variety of options Labial herpes Shingels Alzheimer Rheumatoid arthritis Know-how in polymerases & proteases Pain Multiple sclerosis Osteoporosis HIV Bacterial infections Asthma COPD Hepatitis

  4. Medivir: the strategic journey 2003 200X Pharma 200x • Polymerase and protease inhibitorsin clinical • development • Aim for product swaps in coming partnerships. • First product launch from own pipeline. • Research based pharmaceutical company with a • sales force focusing on specialist products for • the Nordic region. • Polymerase inhibitors in clinical development • and protease inhibitors in pre clinical research. • Research based biotech company. • Broad range of partnerships. • Nordic marketing rights to all projects. • Approximately 120 employees.

  5. Unique Selling Propositions in all clinical projects • Valomaciclovir (RP 606) - shingles - Expected to reduce Post-herpetic neuralgia • ME 609 – labial herpes -Expected to prevent ulcerative lesions • Alovudine (MIV 310) - HIV-NRTI • - Excellent activity against multiresistant strains • - Once daily dosing • MIV 210 – HIV-NRTI • - Excellent activity against multiresistant strains • - High oral bioavailability

  6. Medivir’s pipeline Discovery Lead Optimisation Preclinical IND Phase I Phase II Phase III NDA Market identification phase development RP-606 Shingles ME-609 Labial herpes MIV-310 NRTI Multiresistant HIV MIV-210 NRTI Multiresistant HIV MIV-150 HIV-NNRTI Population Council MV026048 HIV-NNRTI (Roche has an opt in) Cathepsin S RA, MS, Pain Cathepsin K Osteoporosis MIV-170 HIV-NNRTI HCV HCV Hepatitis Polymerase inhibitor Polymerase inhibitor combination Alzheimer Protease inhibitor Other Discovery activities in protease and polymerase

  7. Balancing risk Five individual projects in clinical development RP-606 Shingles ME-609 Labial herpes MIV-310 NRTI Multiresistent HIV MIV-210 Total deal value > 2.000m SEK MIV-150 Population Council Partners in four clinical projects MV026048 Cath S Three Joint Ventures Cath K Five individualprojects able to generate royalty MIV-170 HCV Four individual projects able to generate milestones HCV Alzheimer

  8. High Market Potential* Even if there isn't any drug preventing labial or genital herpes, sales amounted to more than 500m USD in 2002 Sales of shingles drugs > 1.000m USD in 2002. None of the existing drugs have a claim for PHN RP-606 ME-609 MIV-310 MIV-210 MIV-150 Sales of HIV drugs amounted to 5.300m USD in 2002. NRTI’s represented 60% and are expected to grow their market share above 70% in the coming five years. Population Council MV026048 MIV-170 Growing share of multiresistant HIV. MIV-310 and 210 are developed to address this. Cath S Cath K HCV HCV Alzheimer * Market data accrding to IMS-data

  9. The Late Stage Preclinical Pipeline Discovery Lead Optimisation Late preclinical IND Phase I Phase II Phase III NDA Market identification phase development MV026048 A new treatment paradigm for RA, MS and asthma. Possible improvements over TNF-alpha blockers. Cath S Cath K MIV-170 HCV HCV New treatment paradigm for osteoporosis and osteoarthritis. Present therapies like, bisphosphonates and HRT all have limitations Alzheimer Strong presence in hepatitis C Polymerase inhibitor Protease inhibitor

  10. Financial status 31th of December 2003 • Result after financial items amounted to till SEK -40,3 (-59,8 )m. • SEK 250m in cash. • Net R&D costs for 2004 will be approximately SEK 175m, this is in line with previous years. • The Q1 report will be published on the 22 April. • AGM will be held on the 22 April.

  11. Medivir’s 15 largest shareholders • Listed on • Attract-40 • Free float: 90% • 5.100 Shareholders • Market value: • 1.100m SEK

  12. Pharma World leader in drugs inhibiting proteases and polymerases

  13. www.medivir.se

More Related